Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INDV Stock Forecast 2025-2026
$11.26
Current Price
$1.41B
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to INDV Price Targets
+42.1%
To High Target of $16.00
+33.2%
To Median Target of $15.00
+15.5%
To Low Target of $13.00
INDV Price Momentum
-0.7%
1 Week Change
+4.6%
1 Month Change
-35.2%
1 Year Change
-9.4%
Year-to-Date Change
-39.4%
From 52W High of $18.59
+53.6%
From 52W Low of $7.33
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Indivior (INDV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on INDV and similar high-potential opportunities.
Latest INDV Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, INDV has a bullish consensus with a median price target of $15.00 (ranging from $13.00 to $16.00). Currently trading at $11.26, the median forecast implies a 33.2% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Amsellem at Piper Sandler, projecting a 42.1% upside. Conversely, the most conservative target is provided by David Amsellem at Piper Sandler, suggesting a 15.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INDV Analyst Ratings
7
Buy
0
Hold
0
Sell
INDV Price Target Range
Low
$13.00
Average
$15.00
High
$16.00
Current: $11.26
Latest INDV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INDV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2025 | Piper Sandler | David Amsellem | Overweight | Maintains | $13.00 |
| Oct 25, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $16.00 |
| Oct 11, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $15.00 |
| Oct 11, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $16.00 |
| Sep 13, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $22.00 |
| Jul 23, 2024 | Piper Sandler | David Amsellem | Overweight | Initiates | $22.00 |
| Jul 10, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $24.00 |
| Apr 3, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $37.00 |
Indivior PLC (INDV) Competitors
The following stocks are similar to Indivior based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Indivior PLC (INDV) Financial Data
Indivior PLC has a market capitalization of $1.41B with a P/E ratio of 530.5x. The company generates $1.17B in trailing twelve-month revenue with a -5.3% profit margin.
Revenue growth is -6.3% quarter-over-quarter, while maintaining an operating margin of +25.6% and return on equity of -0.6%.
Valuation Metrics
Market Cap
$1.41B
Enterprise Value
$1.40B
P/E Ratio
530.5x
PEG Ratio
10.5x
Price/Sales
1.2x
Growth & Margins
Revenue Growth (YoY)
-6.3%
Gross Margin
+83.5%
Operating Margin
+25.6%
Net Margin
-5.3%
EPS Growth
-23.0%
Financial Health
Cash/Price Ratio
+26.6%
Current Ratio
0.9x
Debt/Equity
-1.3x
ROE
-0.6%
ROA
+12.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Indivior PLC (INDV) Business Model
About Indivior PLC
What They Do
Develops medications for addiction and mental health.
Business Model
Indivior PLC operates as a specialty pharmaceutical company focused on the development and commercialization of treatments for addiction, particularly opioid dependence. The company generates revenue primarily through the sales of its innovative medications, which are distributed globally to healthcare providers and patients, addressing a critical need in public health.
Additional Information
Headquartered in Richmond, Virginia, Indivior is recognized for its commitment to scientific research and evidence-based solutions. Its dedication to tackling opioid addiction positions it as a key player in both the pharmaceutical industry and public health sectors, catering to the increasing demand for effective healthcare interventions.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,030
CEO
Mr. Mark Crossley
Country
United States
IPO Year
2014
Website
www.indivior.comIndivior PLC (INDV) Latest News & Analysis
Latest News
Quick Summary
Indivior PLC will participate in the Jefferies Global Healthcare Conference on June 4, 2025, with CEO Joe Ciaffoni and CFO Ryan Preblick hosting meetings.
Why It Matters
Indivior PLC's participation in key investor events signals its commitment to transparency and engagement, potentially influencing investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Indivior PLC announced a study showing that SUBLOCADE use during pregnancy does not increase the risk of birth defects, miscarriage, or maternal complications, published in the American Journal on Addictions.
Why It Matters
The study's findings may enhance SUBLOCADE's market potential, reduce regulatory scrutiny, and attract investors seeking growth in the opioid treatment sector, particularly in the maternal health niche.
Source: PRNewsWire
Market Sentiment:
Neutral
Indivior: Trying To Break Addiction
25 days ago
Quick Summary
Indivior PLC faces competition and poor performance but may recover under a new CEO. Analysts project growth in the buprenorphine market, despite litigation risks and financial challenges.
Why It Matters
Indivior PLC's stock may rebound with leadership changes and FDA approvals amid competition. Analysts foresee growth potential in the buprenorphine market, despite existing risks.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Indivior PLC will hold its Q1 2025 earnings conference call on April 24, 2025, at 8:00 AM ET, featuring key executives and analysts from various financial institutions.
Why It Matters
Indivior's Q1 2025 earnings call will provide insights into financial performance, strategic direction, and market outlook, crucial for assessing the company's investment potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Indivior Announces Q1 2025 Financial Results
1 month ago
Quick Summary
Indivior PLC announced its financial results for Q1 2025, ending March 31. Further details on performance were not included in the excerpt.
Why It Matters
Indivior's financial results can impact stock performance, investor sentiment, and market expectations, influencing investment decisions and valuations.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Indivior PLC (INDV) reported Q3 earnings of $0.41 per share, surpassing the Zacks Consensus Estimate of $0.22, and up from $0.37 per share year-over-year.
Why It Matters
Indivior's earnings beat expectations and show year-over-year growth, indicating strong performance and potential for increased investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About INDV Stock
What is Indivior PLC's (INDV) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Indivior PLC (INDV) has a median price target of $15.00. The highest price target is $16.00 and the lowest is $13.00.
Is INDV stock a good investment in 2025?
According to current analyst ratings, INDV has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INDV stock?
Wall Street analysts predict INDV stock could reach $15.00 in the next 12 months. This represents a 33.2% increase from the current price of $11.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Indivior PLC's business model?
Indivior PLC operates as a specialty pharmaceutical company focused on the development and commercialization of treatments for addiction, particularly opioid dependence. The company generates revenue primarily through the sales of its innovative medications, which are distributed globally to healthcare providers and patients, addressing a critical need in public health.
What is the highest forecasted price for INDV Indivior PLC?
The highest price target for INDV is $16.00 from David Amsellem at Piper Sandler, which represents a 42.1% increase from the current price of $11.26.
What is the lowest forecasted price for INDV Indivior PLC?
The lowest price target for INDV is $13.00 from David Amsellem at Piper Sandler, which represents a 15.5% increase from the current price of $11.26.
What is the overall INDV consensus from analysts for Indivior PLC?
The overall analyst consensus for INDV is bullish. Out of 2 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are INDV stock price projections?
Stock price projections, including those for Indivior PLC, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 3:20 AM UTC